# Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer

> **NCT01470742** · PHASE3 · WITHDRAWN · sponsor: **Samsung Medical Center**

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** XELOX
- **DRUG:** XELODA

## Key facts

- **NCT ID:** NCT01470742
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-09
- **Primary completion:** 2015-02
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We stop because of problems such as insurance.
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470742, "Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01470742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*